INT17890

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1991
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 26
Total Number 29
Disease Relevance 12.05
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (HMGCR) oxidoreductase activity (HMGCR) endoplasmic reticulum (HMGCR)
peroxisome (HMGCR)
Anatomy Link Frequency
liver 1
bile 1
body 1
T-cell 1
HMGCR (Homo sapiens)
Pain Link Frequency Relevance Heat
Bile 199 99.52 Very High Very High Very High
aspirin 13 99.48 Very High Very High Very High
Calcium channel 7 96.76 Very High Very High Very High
Endep 1 94.60 High High
Inflammatory response 25 92.40 High High
beta blocker 45 90.40 High High
Inflammation 223 89.84 High High
anesthesia 4 83.28 Quite High
isoflurane 4 82.00 Quite High
cINOD 26 73.88 Quite High
Disease Link Frequency Relevance Heat
Cognitive Disorder 71 98.36 Very High Very High Very High
Disease 333 98.32 Very High Very High Very High
Disorder Of Lipid Metabolism 984 97.88 Very High Very High Very High
Coronary Artery Disease 597 97.56 Very High Very High Very High
Adhesions 30 97.32 Very High Very High Very High
Hyperlipidemia 59 97.24 Very High Very High Very High
Diabetes Mellitus 122 95.80 Very High Very High Very High
Metabolic Syndrome 38 95.24 Very High Very High Very High
Xanthomatosis 9 94.64 High High
Lung Cancer 69 94.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, has been administered to approximately 2,400 patients with primary hypercholesterolemia with a mean follow-up of 1 year in controlled clinical studies and their open extensions.
Negative_regulation (inhibitor) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase associated with hyperlipidemia
1) Confidence 0.42 Published 1991 Journal Am. J. Cardiol. Section Abstract Doc Link 1951069 Disease Relevance 0.16 Pain Relevance 0
Patients suffering from sitosterolemia have severely depressed hepatic cholesterol biosynthesis, and decreased levels of HMG-CoA reductase enzyme [37].
Negative_regulation (decreased) of HMG-CoA reductase
2) Confidence 0.37 Published 2004 Journal Lipids Health Dis Section Body Doc Link PMC524501 Disease Relevance 0.68 Pain Relevance 0.03
Other common concomitant medications included HMG-CoA reductase inhibitors, diuretics, acetylsalicylic acid, angiotensin converting enzyme inhibitors, and calcium channel blockers.
Negative_regulation (inhibitors) of HMG-CoA reductase associated with aspirin and calcium channel
3) Confidence 0.36 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2822745 Disease Relevance 0.34 Pain Relevance 0.28
Inhibition of HMG-CoA reductase disrupts cholesterol biosynthesis, thereby lowering total cholesterol in the body.
Negative_regulation (Inhibition) of HMG-CoA reductase in body associated with disorder of lipid metabolism
4) Confidence 0.22 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 0.38 Pain Relevance 0.03
Currently, the 3-hydroxy-3-methylgutaryl coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors) have proven to significantly decrease LDL-C levels, reduce CHD morbidity/mortality and improve overall survival.
Negative_regulation (inhibitors) of HMG-CoA reductase associated with coronary artery disease
5) Confidence 0.16 Published 2010 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2835557 Disease Relevance 1.05 Pain Relevance 0
ATP III is based on evidence from a number of studies, most of which focus on HMG-CoA reductase inhibitors, also known as statins, which have the greatest effect on LDL-C.
Negative_regulation (inhibitors) of HMG-CoA reductase
6) Confidence 0.16 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.05 Pain Relevance 0.03
HMG-CoA reductase inhibitors (statins)
Negative_regulation (inhibitors) of HMG-CoA reductase
7) Confidence 0.16 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 0.53 Pain Relevance 0.04
There are several classes of drugs on the market for lipid management, including HMG-CoA reductase inhibitors (statins), bile acid sequestrants, niacin (nicotinic acid), fibric acid derivatives, and cholesterol absorption inhibitors.
Negative_regulation (inhibitors) of HMG-CoA reductase in bile associated with bile
8) Confidence 0.16 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 0.63 Pain Relevance 0.05
and atorvastatin in the presence or absence of mevalonate, FPP, and GGPP to determine whether atorvastatin inhibition of ENA-78 production was dependent on HMG-CoA reductase inhibition and subsequent downstream pathways.
Spec (whether) Negative_regulation (inhibition) of HMG-CoA reductase
9) Confidence 0.14 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0 Pain Relevance 0
To determine whether atorvastatin effects were dependent on HMG-CoA reductase inhibition, HUVECs were cultured with IL-1?
Spec (whether) Negative_regulation (inhibition) of HMG-CoA reductase
10) Confidence 0.14 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.06 Pain Relevance 0.03
have been reported for lovastatin (an HMG-CoA reductase inhibitor) and the PPAR?
Negative_regulation (inhibitor) of HMG-CoA reductase
11) Confidence 0.10 Published 2008 Journal PPAR Research Section Body Doc Link PMC2515882 Disease Relevance 0.48 Pain Relevance 0.03
Inhibition of HMG-CoA reductase leads to upregulation of low-density lipoprotein cholesterol (LDL-C) receptors in the liver, mediated by activation of sterol regulatory element-binding proteins resulting in enhanced clearance of LDL from the circulation and thus has an important role in preventing atherosclerosis.
Negative_regulation (Inhibition) of HMG-CoA reductase in liver associated with atherosclerosis
12) Confidence 0.10 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686256 Disease Relevance 0.52 Pain Relevance 0.12
Caution must be exercised with concurrent administration of drugs that interfere with the CYP system in the presence of HMG-CoA reductase inhibitors.
Negative_regulation (inhibitors) of HMG-CoA reductase
13) Confidence 0.10 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2615789 Disease Relevance 0.23 Pain Relevance 0.05
Since statins are highly selective inhibitors of HMG-CoA reductase, drug-drug interactions are mainly pharmacokinetic, rather than pharmacodynamic.
Negative_regulation (inhibitors) of HMG-CoA reductase
14) Confidence 0.08 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2546474 Disease Relevance 0.33 Pain Relevance 0
The third mechanism is unrelated to inhibition of HMG-CoA reductase, and consist in blocking the interaction between LFA-1 and ICAM-1 adhesion molecules [30], which is crucial to stabilize antigen presenting cell/T-cell contact during antigen presentation and to regulate the traffic of leukocytes during homeostatic and inflammatory conditions [31,32].
Negative_regulation (inhibition) of HMG-CoA reductase in T-cell associated with inflammation and adhesions
15) Confidence 0.07 Published 2009 Journal Trials Section Body Doc Link PMC2705367 Disease Relevance 0.44 Pain Relevance 0.11
have been reported for lovastatin (an HMG-CoA reductase inhibitor) and the PPAR-?
Negative_regulation (inhibitor) of HMG-CoA reductase
16) Confidence 0.07 Published 2007 Journal PPAR Research Section Body Doc Link PMC2220082 Disease Relevance 0.42 Pain Relevance 0.03
Given the prolonged duration of HMG-CoA reductase inhibition achieved with atorvastatin, many trials have been conducted to evaluate the efficacy of alternate-day dosing of this drug compared with the standard once-daily dosing.
Negative_regulation (inhibition) of HMG-CoA reductase
17) Confidence 0.06 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2546474 Disease Relevance 0.40 Pain Relevance 0
HMG-CoA reductase inhibitors reduce the production of mevalonic acid from HMG-CoA, resulting in a reduction in hepatic cholesterol synthesis.
Negative_regulation (reduce) of HMG-CoA reductase
18) Confidence 0.06 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2546474 Disease Relevance 0.14 Pain Relevance 0
The first two are based on the inhibition of HMG-CoA reductase described above.
Negative_regulation (inhibition) of HMG-CoA reductase
19) Confidence 0.05 Published 2009 Journal Trials Section Body Doc Link PMC2705367 Disease Relevance 0.38 Pain Relevance 0.05
Statins inhibit HMG-CoA reductase and decrease the production of mevalonate, geranyl pyrophosphate, and farnesyl pyrophosphate, and subsequent products on the way to construction of the cholesterol molecule.
Negative_regulation (inhibit) of HMG-CoA reductase
20) Confidence 0.05 Published 2007 Journal Immun Ageing Section Body Doc Link PMC1845171 Disease Relevance 0.14 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox